Pharmacokinetics and bioequivalence of parenterally administered doramectin in cattle

Abstract

Plasma concentrations of doramectin in 40 cattle dosed by subcutaneous (sc) or intramuscular (i.m.) injection (200 μg/kg) were compared to assess the bioequivalence of the two routes of administration. Peak concentration (C_max), and areas under the concentration curve (AUC_0–) were determined from plasma concentrations. Animals treated by the sc route showed a mean AUC_0– of 457 ± 66 ng±day/mL (± SD) and a mean C_max of 27.8 ± 7.9 ng/mL. Results from the i.m. treatment group showed a mean AUC_0– of 475 ± 82 ng-day/mL and a mean C_max of 33.1 ± 9.0 ng/mL Absorption constants (k_a) determined by modelling were 0.542 ± 0.336 day^-1after sc administration and 0.710 ± 0.357 day^-1after i.m. administration. The 90% confidence limits on the difference between mean AUC_0– values for the sc and i.m. groups fell within 20% of the mean value for the subcutaneous group. C_max was somewhat greater for the i.m. route. The 90% confidence limits on the difference in mean In (T_max+1) also fell within 20% of the mean sc value. Based on this analysis, bioequivalence of the sc and i.m. formulation has been established.